An article in USA Today discusses the high costs associated with a new gene therapy treatment. Kymriah, a leukemia drug, has a high initial cost that rises even higher because of associated treatments, such as those to manage side effects. The article quotes Dr. Gellad, who notes that the drug has low manufacturing costs. Others quoted discuss the benefits and challenges of pricing plan, called "outcomes-based pricing" offered by the drug's manufacturer, Novartis. The plan will only charge patients who go into reminssion within one month of treatment. Those quoted in the article agree with Dr. Gellad that Kymriah is too expensive, and others add that the outcomes of the outcomes-based pricing are inappropriate and should encompass a longer time frame.